Evidence map›Paper›PMID 37664167›Full record

ArticleInternational journal of cardiology. Cardiovascular risk and prevention2023

The hypertension-based chronic disease model in a primary care setting.

Eduardo Thadeu de Oliveira Correia, Jeffrey I Mechanick, Antonio José Lagoeiro Jorge, Leticia Mara Dos Santos Barbetta, Maria Luiza Garcia Rosa, Adson Renato Leite, Dayse Mary da Silva Correia, Evandro Tinoco Mesquita

Open access · goldAbstract read
In one paragraph

Article in International journal of cardiology. Cardiovascular risk and prevention, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. The dominant driver paradigm of cardiometabolic care.American journal of preventive cardiology · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Eduardo Thadeu de Oliveira CorreiaDepartment of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Jeffrey I MechanickMarie-Josée and Henry R. Kravis Center for Clinical Cardiovascular Health at Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Antonio José Lagoeiro JorgeUniversidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil.
Leticia Mara Dos Santos BarbettaUniversidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil.
Maria Luiza Garcia RosaUniversidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil.
Adson Renato LeiteUniversidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil.
Dayse Mary da Silva CorreiaUniversidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil.
Evandro Tinoco MesquitaUniversidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil.
Universidade Federal Fluminense · BRIcahn School of Medicine at Mount Sinai · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Driver-based chronic disease models address the public health challenge of cardiometabolic risk. However, there is no data available about the novel Hypertension-Based Chronic Disease (HBCD) model. This study investigates the prevalence, characteristics, and prognostic significance of HBCD Stages in a primary care cohort. Methods: This study included participants aged ≥45 years, randomly selected from the primary care program of a Brazilian medium-sized city. Participants underwent electrocardiogram, tissue Doppler echocardiogram and were followed for a median of 6 years. Participants were classified into HBCD Stages as follows: Stage 1: hypertension risk factors; Stage 2: pre-hypertension; Stage 3: hypertension; and Stage 4: hypertension complications. Results: Overall, 633 participants were included in the cross-sectional analysis and 560 that had follow-up data were included in the prognostic analysis. From 633 participants, 1.3% had no identifiable risk factors for HBCD, 10.0% were Stage 1, 14.7% Stage 2, 51.5% Stage 3, and 22.5% Stage 4. Increasing HBCD stages had worse glomerular filtration rates, echocardiographic markers, and higher body mass index, waist circumference, blood glucose levels, and prevalence of type 2 diabetes. Rates of all-cause mortality or cardiovascular hospitalization increased across HBCD Stages: Stage 1: 3.6%; Stage 2: 4.8%, Stage 3: 7.6%; and Stage 4: 39.5%. Kaplan-Meier curves showed composite outcome worsened across HBCD Stages 1-4 (p < 0.001). Conclusions: HBCD is a conceptually and prognostically valid model. Remarkably, HBCD stages were associated with progressively worsening markers of heart disease, declining kidney function and higher rates of all-cause mortality or cardiovascular hospitalization.

Indexed as

Blood pressureCardiometabolic diseaseHypertensionPrehypertension

Identifiers

PMID37664167
PMCPMC10470300
OpenAlexW4385813847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.